Evidence map›Paper›PMID 26498592›Full record

ReviewDiabetologia2016

Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.

R David Leslie, Jerry Palmer, Nanette C Schloot, Ake Lernmark

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 5 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 5 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Characterization of Turner Syndrome-associated Diabetes Mellitus.The Journal of clinical endocrinology and metabolism · 2025
    Article
  14. Article
  15. Article
  16. SGLT2 inhibitor use in the management of feline diabetes mellitus.Journal of veterinary pharmacology and therapeutics · 2025
    Review
  17. Article
  18. Article
  19. Diabetes Study of Children of Diverse Ethnicity and Race: Study design.Diabetes/metabolism research and reviews · 2024
    Observational
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

R David LeslieBlizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, E1 2AT, UK. r.d.g.leslie@qmul.ac.uk.
Jerry PalmerUniversity of Washington, VA Puget Sound Health Care System, Seattle, USA.
Nanette C SchlootInstitute for Clinical Diabetology at the German Diabetes Center, Heinrich-Heine University, Düsseldorf, Germany.
Ake LernmarkDepartment of Clinical Sciences, Lund University/CRC, Malmö, Sweden.
Deutsches Diabetes-Zentrum e.V. · DELund University · SEQueen Mary University of London · GBUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is not a single homogeneous disease but composed of many diseases with hyperglycaemia as a common feature. Four factors have, historically, been used to identify this diversity: the age at onset; the severity of the disease, i.e. degree of loss of beta cell function; the degree of insulin resistance and the presence of diabetes-associated autoantibodies. Our broad understanding of the distinction between the two major types, type 1 diabetes mellitus and type 2 diabetes mellitus, are based on these factors, but it has become apparent that they do not precisely capture the different disease forms. Indeed, both major types of diabetes have common features, encapsulated by adult-onset autoimmune diabetes and maturity-onset diabetes of the young. As a result, there has been a repositioning of our understanding of diabetes. In this review, drawing on recent literature, we discuss the evidence that autoimmune type 1 diabetes has a broad clinical phenotype with diverse therapeutic options, while the term non-autoimmune type 2 diabetes obscures the optimal management strategy because it encompasses substantial heterogeneity. Underlying these developments is a general progression towards precision medicine with the need for precise patient characterisation, currently based on clinical phenotypes but in future augmented by laboratory-based tests.

Indexed as

Age FactorsAllelesAutoantibodiesAutoimmunityC-PeptideDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease ProgressionGenotypeHumansHyperglycemiaInsulinInsulin ResistancePhenotypeAutoantibodiesC-PeptideInsulin

Identifiers

PMID26498592
OpenAlexW1894478766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.